- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00826150
Phase 1/2a Study of DTA-H19 in Advanced Stage Ovarian Cancer
Phase 1/2a, Dose-Escalation, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Intraperitoneal Administration of DTA-H19 in Subjects With Advanced Stage Ovarian Cancer
Studienübersicht
Detaillierte Beschreibung
This is a Phase 1/2a, open label, dose escalation, repeat dose study in 11 subjects with recurrent, platinum resistant advanced stage ovarian cancer or primary peritoneal carcinoma designed to determine the tolerability, safety, quality of life, PK, and preliminary efficacy of DTA-H19 administered intraperitoneally(IP).
Primary Objective: The primary objectives of this study are:
- To determine the maximum tolerated dose (MTD) of IP DTA-H19; and,
- To identify any dose limiting toxicities (DLTs).
Secondary Objectives: Secondary objectives of this study are:
- To determine quality of life of subjects with advanced ovarian cancer, primary peritoneal carcinoma treated with IP DTA-H19;
- To determine the the reduction in malignant ascites as measured by Ultrasound and change in frequency of parecenteses necessary.
- To determine the overall survival distribution.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
- Phase 1
Kontakte und Standorte
Studienorte
-
-
-
Holon, Israel
- The Edith Wolfson Medical Center
-
Jerusalem, Israel
- Hadassah University Hospital
-
Kfar Saba, Israel
- Meir Hospital
-
Tel Hashomer, Israel
- Sheba Medical Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Provide written informed consent and be at least 18 years of age.
- Have histopathologically documented epithelial ovarian carcinoma or primary peritoneal carcinoma with evidence of ascites.
- Have either a) platinum-refractory disease (i.e. persistent disease following completion of platinum-based primary chemotherapy) and have failed at least primary platinum-based chemotherapy; or b) platinum-resistant recurrent disease and have failed at least one regimen of second line chemotherapy.
- Be able to tolerate placement of IP catheter.
- Be at least 2 weeks from last treatment to allow recovery from prior toxicity but in the judgment of the investigator with sufficient time to ensure that the effects of prior treatments will not confound safety evaluations.
- Have a Karnofsky performance status score of ≥ 70%.
- Not be of child-bearing potential.
- Have a life expectancy of ≥ 3 months.
- Have serum creatinine < 2.0 mg/dL, total bilirubin less than the institution's 3x upper limit of normal (ULN); AST and ALT <= 2.5 x ULN,total albumin ≥ 2.5 g/dL, PT, PTT, and PT/INR within normal limits, absolute neutrophil count (ANC) > 1,500 x 103 cells/mL, platelets ≥ 100,000/mL, and hemoglobin ≥ 10 mg/dL.
- Have a biopsy specimen or an ascites fluid that is positive for H19 expression.
- Have screening procedures completed within 6-weeks before starting treatment.
- No significant history of cardiac disease, i.e., uncontrolled hypertension, unstable angina or congestive heart failure.
- - No plans to receive concurrent chemotherapy, hormonal therapy, radiotherapy, immunotherapy or any other type of therapy for treatment of cancer while on this protocol.
Exclusion Criteria:
- Have evidence of extra abdominal disease with the exception of isolated small nodules (e.g., liver or pulmonary nodules) that are not causing symptoms.
- Have known brain metastases.
- Have known HIV infection.
- Have known active viral or bacterial infections.
- Have presence of any psychological, familiar, sociological, or geographical condition potentially hampering compliance with the study protocol or follow up schedule.
- Have a medical condition contraindicated for laparotomy, laparoscopy, or surgery.
- Have significant bowel involvement denoted by persistent grade 3 vomiting (≥6 episodes in 24 hrs; IV fluids, or total parenteral nutrition (TPN) indicated ≥24 hrs) after removal of ascites, inability to tolerate oral diet or medications, requirement for total parenteral nutrition, or recent (past six weeks) episode of bowel obstruction.
- Have a history of coagulopathy.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: BC-819
BC-819 60, 120 and 240 mg IP administration
|
Cohort #1: 60 mg IP weekly for 3 weeks, one week rest, then repeat for 2 more courses / 60 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course. Cohort #2: 120 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course. Cohort #3: 240 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Number of Participants With Dose-Limiting Toxicities
Zeitfenster: 8 weeks
|
A dose limiting toxicity (DLT) was defined as any grade 3 or greater non-hematologic AE by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE).
If one subject in a cohort experienced a DLT, then three additional subjects had to be enrolled to that cohort unless a second subject in that cohort experiences a DLT.
The next lower dose was to be considered the MTD.
|
8 weeks
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Overall Survival in ITT Population
Zeitfenster: 17.5 months
|
Overall survival, defined as the time from the start of treatment until the subject died, was estimated by Kaplan Meier curves.
|
17.5 months
|
Solid Tumor Response
Zeitfenster: 6 weeks
|
If measurable disease was present, then the response of each marker lesion was evaluated separately and rated for response according to RECIST criteria for solid tumors. Complete Response: Disappearance of the target lesion. Partial Response: At least a 30% decrease in the longest diameter of the target lesion. Stable Disease: No sufficient shrinkage to qualify for partial response, or sufficient increase to qualify for progressive disease. Progressive Disease: At least a 20% increase in the longest diameter of the target lesion. |
6 weeks
|
Systemic BC-819 Pharmacokinetics (PK) by Treatment - T1/2 (Hours)
Zeitfenster: Before the start of the infusion of BC-819 and 2, 4, 6, 8, 24, and 48 hours after the start of the infusion
|
Blood was collected at the indicated time points, then analyzed with a quantitative polymerase chain reaction (Q-PCR) method to quantitate the amount of plasmid present.
|
Before the start of the infusion of BC-819 and 2, 4, 6, 8, 24, and 48 hours after the start of the infusion
|
Systemic BC-819 Pharmacokinetics (PK) - Maximum Observed Plasma Concentration (Cmax)
Zeitfenster: Before the start of the infusion of BC-819 and 2, 4, 6, 8, 24, and 48 hours after the start of the infusion
|
Blood was collected at the indicated time points, then analyzed with a quantitative polymerase chain reaction (Q-PCR) method to quantitate the amount of plasmid present.
|
Before the start of the infusion of BC-819 and 2, 4, 6, 8, 24, and 48 hours after the start of the infusion
|
Systemic BC-819 Pharmacokinetics (PK) by Treatment - Tmax (Hours)
Zeitfenster: Before the start of the infusion of BC-819 and 2, 4, 6, 8, 24, and 48 hours after the start of the infusion
|
Blood was collected at the indicated time points, then analyzed with a quantitative polymerase chain reaction (Q-PCR) method to quantitate the amount of plasmid present.
|
Before the start of the infusion of BC-819 and 2, 4, 6, 8, 24, and 48 hours after the start of the infusion
|
Systemic BC-819 Pharmacokinetics (PK) by Treatment - AUClast
Zeitfenster: Before the start of the infusion of BC-819 and 2, 4, 6, 8, 24, and 48 hours after the start of the infusion
|
Blood was collected at the indicated time points, then analyzed with a quantitative polymerase chain reaction (Q-PCR) method to quantitate the amount of plasmid present.
|
Before the start of the infusion of BC-819 and 2, 4, 6, 8, 24, and 48 hours after the start of the infusion
|
Systemic BC-819 Pharmacokinetics (PK) by Treatment - AUCinf
Zeitfenster: Before the start of the infusion of BC-819 and 2, 4, 6, 8, 24, and 48 hours after the start of the infusion
|
Blood was collected at the indicated time points, then analyzed with a quantitative polymerase chain reaction (Q-PCR) method to quantitate the amount of plasmid present.
|
Before the start of the infusion of BC-819 and 2, 4, 6, 8, 24, and 48 hours after the start of the infusion
|
Overall Survival in PP
Zeitfenster: 17.5 months
|
Overall survival, defined as the time from the start of treatment until the subject died, was estimated by Kaplan Meier curves.
|
17.5 months
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Tally Levy, M.D., The Edith Wolfson Medical Center
- Hauptermittler: David Edelman, MD, Hadassah University Hospital
- Hauptermittler: Ami Fishman, MD, Meir Medical Center
- Hauptermittler: Eitan Rami, MD., Rabin Medical Center
- Hauptermittler: Ofer Lavie, M.D., Carmel Medical Center
- Hauptermittler: Ronnie Shapira-Frommer, MD, Sheba Medical Center
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Neubildungen nach histologischem Typ
- Neubildungen
- Urogenitale Neoplasmen
- Neubildungen nach Standort
- Karzinom
- Neubildungen, Drüsen und Epithelien
- Genitale Neubildungen, weiblich
- Erkrankungen des endokrinen Systems
- Eierstockerkrankungen
- Adnexerkrankungen
- Gonadenstörungen
- Neoplasmen der endokrinen Drüse
- Eierstocktumoren
- Karzinom, Eierstockepithel
Andere Studien-ID-Nummern
- BC-08-01
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur BC-819
-
Anchiano Therapeutics Israel Ltd.AbgeschlossenNeoplasmen der BauchspeicheldrüseVereinigte Staaten, Israel
-
Anchiano Therapeutics Israel Ltd.BeendetNicht-muskelinvasiver Blasenkrebs (NMIBC)Vereinigte Staaten
-
Anchiano Therapeutics Israel Ltd.AbgeschlossenOberflächlicher BlasenkrebsIsrael, Vereinigte Staaten
-
Anchiano Therapeutics Israel Ltd.BeendetBauchspeicheldrüse, AdenokarzinomIsrael, Vereinigte Staaten
-
Anchiano Therapeutics Israel Ltd.AbgeschlossenÜbergangszellkarzinom der BlaseIsrael
-
FAScinate Therapeutics Inc.ParexelRekrutierungParkinson KrankheitVereinigte Staaten
-
Kainos Medicine Inc.AbgeschlossenParkinson-KrankheitKorea, Republik von
-
Kainos Medicine Inc.ParexelRekrutierungMultiple SystematrophieKorea, Republik von
-
Cifarma Cientifica Farmaceutica LtdaUnbekannt
-
Johnson & Johnson Vision Care, Inc.AbgeschlossenKurzsichtigkeitVereinigte Staaten